Hypogonadism Treatment Market Dynamics, Segments and Supply Demand -2025

Hypogonadism is defined as hormonal disorder in which the glands (gonads & ovaries) produce little or no hormones causing its deficiency in the body. Hypogonadism in males refers to deficiency of testosterone due to dysfunction of either of the testes. Female hypogonadism refers to deficiency of estrogen or progesterone due to reduced activity of the ovaries. Hypogonadism is classified into two types: primary hypogonadism (testicular failure) and central hypogonadism (hypothalamic-pituitary axis dysfunction). Other major causes of hypogonadism include autoimmune disorder, genetic disorder, severe infections, and liver and kidney diseases. Generally, hormone and imaging tests are used to diagnose hypogonadism.

Request Sample Copy of the Report@

 https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30392

According to the Boston University School of Medicine, around 4 million to 5 million men in the U.S. were affected with hypogonadism in 2003. The incidence of hypogonadism in men aged between 40 years and 69 years in the country is around 481,000 new cases per year. According to the European Male Aging Study, the prevalence of late onset hypogonadism in men aged between 40 and 79 was 2.1% in 2016. Studies suggest that hypogonadism in adult men is often underdiagnosed and undertreated and only 5%. According to the Urology Care Foundation, hypogonadism is a chronic condition which would require lifelong treatment. The treatment for hypogonadism depends on the cause and concern about fertility and includes treatment such as hormone replacement therapy or assisted reproduction.

Men with heart disease, HIV, COPD, or renal disease have high prevalence of hypogonadism. Factors such as rising prevalence of type 2 diabetes and obesity further increase the incidence of hypogonadism. Growth of the global hypogonadism treatment market is attributed to rise in geriatric population, increase in infertility, and improved diagnosis. However, growing concerns about the potential side effects, availability of generic drugs, and preference for other natural hormonal boosters and supplements are likely to hamper the growth of the hypogonadism treatment market. Increasing awareness, awaiting approvals for new generation drugs in pipeline, and technological advancements present significant opportunities in the hypogonadism treatment market.

The primary treatment option for hypogonadism is hormone replacement therapy. Based on product type, the market has been classified into testosterone replacement therapy, estrogen therapy, and progesterone therapy. Testosterone replacement therapy is the fastest growing segment as hypogonadism is more prevalent in men. The segment is expected to hold major share of the global market during the forecast period.

In terms of mode of administration, the hypogonadism treatment market has been broadly classified into transdermal patch, topical gel, buccal tablets, implantable pellet, intramuscular injections, and oral tablets. Transdermal patch followed by topical gels are anticipated to be the fastest growing segments as these provide steady route of administration and are easily modifiable over a short period of time. The oral and buccal tablets segments are anticipated to experience sluggish growth during the forecast period due to high side effects and liver diseases.

Based on the distribution channel they are segmented into hospital pharmacies, retail pharmacies and others. The major market share for the hypogonadism treatment market is for the retail pharmacies segment and is anticipated to rule the market during the forecast period as continuous long term treatment is required for the hypogonadism patient.

In terms of region, the global hypogonadism treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest market for hypogonadism treatment, accounting for more than half of the market share due to the factors such as increased adoption of newer highly advanced products, rising awareness about hormonal disorder including various treatment options available, and advancing health care infrastructure. However, Asia Pacific is anticipated to be the fastest growing market during the forecast period due to increasing urbanization and rise in the patient population.

Key players in the global hypogonadism treatment market are Bayer AG, Abbott Laboratories, Inc., Merck Serono, Sanofi, Merck & Co., Inc., Actavis, Inc., AbbVie Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Endo International plc, Ferring Holding S.A., and Laboratoires Genevrier.

Request TOC of the Report@

 https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=30392

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis
The regional analysis covers:

North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com/

This release was published on openPR.